U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

Pfizer, Astellas expand PADCEV-Keytruda label with FDA nod in bladder cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s PFE and Astellas Pharma Inc.’s ALPMF ALPMY ...
Cancer Therapy Advisor

Pathologic Complete Response vs ctDNA Remains Essential for Solid Cancer Prognostication

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...
Medscape

Neoadjuvant Therapy Use Rising Sharply in Cancer Care

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...
Medical Xpress

ctDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...
ascopubs.org

Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized ...

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer Neoadjuvant approaches ...
ascopubs.org

Exploration of neoadjuvant therapy regimens and prediction of immune effects for HER2-positive locally advanced breast cancer.

MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours. This is an ASCO Meeting ...
Nasdaq

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, ...